Proteins > Amyloid-beta precursor protein
Page last updated: 2024-08-07 15:38:46
Amyloid-beta precursor protein
An amyloid-beta precursor protein that is encoded in the genome of human. [PRO:DAN]
Synonyms
APP;
ABPP;
APPI;
Alzheimer disease amyloid protein;
Amyloid precursor protein;
Amyloid-beta A4 protein;
Cerebral vascular amyloid peptide;
CVAP;
PreA4;
Protease nexin-II;
PN-II
Research
Bioassay Publications (91)
Timeframe | Studies on this Protein(%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 14 (15.38) | 29.6817 |
2010's | 65 (71.43) | 24.3611 |
2020's | 12 (13.19) | 2.80 |
Compounds (160)
Drugs with Potency Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
[3-carboxy-2-(1-oxohexadecoxy)propyl]-trimethylammonium | Homo sapiens (human) | Potency | 20.5962 | 1 | 0 |
1,10-phenanthroline | Homo sapiens (human) | Potency | 18.3564 | 1 | 0 |
3,4-dichloroisocoumarin | Homo sapiens (human) | Potency | 23.1093 | 1 | 0 |
p-chloromercuribenzoic acid | Homo sapiens (human) | Potency | 4.6109 | 1 | 0 |
6-nitroso-1,2-benzopyrone | Homo sapiens (human) | Potency | 16.3601 | 1 | 0 |
cantharidin | Homo sapiens (human) | Potency | 23.1093 | 1 | 0 |
dephostatin | Homo sapiens (human) | Potency | 29.0929 | 1 | 0 |
dequalinium | Homo sapiens (human) | Potency | 16.3601 | 1 | 0 |
disulfiram | Homo sapiens (human) | Potency | 5.1735 | 1 | 0 |
2,3-dimethoxy-1,4-naphthoquinone | Homo sapiens (human) | Potency | 29.0929 | 1 | 0 |
ebastine | Homo sapiens (human) | Potency | 29.0929 | 1 | 0 |
ebselen | Homo sapiens (human) | Potency | 16.3601 | 1 | 0 |
fluorouracil | Homo sapiens (human) | Potency | 18.3564 | 1 | 0 |
1-(2-naphthalenyl)-3-[(phenylmethyl)-propan-2-ylamino]-1-propanone | Homo sapiens (human) | Potency | 18.3564 | 1 | 0 |
lansoprazole | Homo sapiens (human) | Potency | 29.0929 | 1 | 0 |
beta-lapachone | Homo sapiens (human) | Potency | 29.0929 | 1 | 0 |
mitoxantrone | Homo sapiens (human) | Potency | 23.1093 | 1 | 0 |
ACar 18-0 | Homo sapiens (human) | Potency | 5.8048 | 1 | 0 |
tyrphostin a9 | Homo sapiens (human) | Potency | 2.5929 | 1 | 0 |
idarubicin | Homo sapiens (human) | Potency | 23.1093 | 1 | 0 |
3-octadecanamido-2-ethoxypropylphosphocholine | Homo sapiens (human) | Potency | 29.0929 | 1 | 0 |
zpck | Homo sapiens (human) | Potency | 14.5810 | 1 | 0 |
selenomethylselenocysteine | Homo sapiens (human) | Potency | 18.3564 | 1 | 0 |
abt 980 | Homo sapiens (human) | Potency | 29.0929 | 1 | 0 |
tosylphenylalanyl chloromethyl ketone | Homo sapiens (human) | Potency | 16.3601 | 1 | 0 |
5,11-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol | Homo sapiens (human) | Potency | 29.0929 | 1 | 0 |
6-bromoindirubin-3'-oxime | Homo sapiens (human) | Potency | 18.3564 | 1 | 0 |
ketoconazole | Homo sapiens (human) | Potency | 7.3078 | 1 | 0 |
IPA-3 | Homo sapiens (human) | Potency | 8.1995 | 1 | 0 |
isoliquiritigenin | Homo sapiens (human) | Potency | 16.3601 | 1 | 0 |
3,4-methylenedioxy-beta-nitrostyrene | Homo sapiens (human) | Potency | 2.0596 | 1 | 0 |
phenylthiazolylthiourea | Homo sapiens (human) | Potency | 9.2000 | 1 | 0 |
(2'-(4-aminophenyl)-(2,5'-bi-1h-benzimidazol)-5-amine) | Homo sapiens (human) | Potency | 29.0929 | 1 | 0 |
stattic | Homo sapiens (human) | Potency | 5.8048 | 1 | 0 |
1,4-bis[2-(4-hydroxyphenyl)ethylamino]anthracene-9,10-dione | Homo sapiens (human) | Potency | 18.3564 | 1 | 0 |
LSM-1318 | Homo sapiens (human) | Potency | 0.2311 | 1 | 0 |
cyclosporine | Homo sapiens (human) | Potency | 4.6109 | 1 | 0 |
n-oleoyldopamine | Homo sapiens (human) | Potency | 20.5962 | 1 | 0 |
as 604850 | Homo sapiens (human) | Potency | 20.5962 | 1 | 0 |
bay 11-7082 | Homo sapiens (human) | Potency | 2.3109 | 1 | 0 |
bay 11-7085 | Homo sapiens (human) | Potency | 1.1582 | 1 | 0 |
cisplatin | Homo sapiens (human) | Potency | 20.5962 | 1 | 0 |
6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2h-pyran-2-one | Homo sapiens (human) | Potency | 23.1093 | 1 | 0 |
b 43 | Homo sapiens (human) | Potency | 29.0929 | 1 | 0 |
edelfosine | Homo sapiens (human) | Potency | 29.0929 | 1 | 0 |
17-cyclopropylmethyl-6,7-didehydro-4,5-epoxy-5'-guanidinyl-3,14-dihydroxyindolo(2',3'-6,7)morphinan | Homo sapiens (human) | Potency | 5.1735 | 1 | 0 |
calcimycin | Homo sapiens (human) | Potency | 1.4581 | 1 | 0 |
ucl 2077 | Homo sapiens (human) | Potency | 18.3564 | 1 | 0 |
(E,E)-1-bromo-2,5-bis-(4-hydroxystyryl)benzene | Homo sapiens (human) | Potency | 29.0929 | 1 | 0 |
ag-879 | Homo sapiens (human) | Potency | 5.1735 | 1 | 0 |
Drugs with Inhibition Measurements
Drugs with Activation Measurements
Drugs with Other Measurements
Design, synthesis and evaluation of novel tacrine-multialkoxybenzene hybrids as multi-targeted compounds against Alzheimer's disease.European journal of medicinal chemistry, , Jun-30, Volume: 116, 2016
Synthesis, molecular docking and biological evaluation of N,N-disubstituted 2-aminothiazolines as a new class of butyrylcholinesterase and carboxylesterase inhibitors.Bioorganic & medicinal chemistry, , Mar-01, Volume: 24, Issue:5, 2016
Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer's disease.Bioorganic & medicinal chemistry, , 09-01, Volume: 45, 2021
Design, synthesis and biological evaluation of novel deoxyvasicinone-indole as multi-target agents for Alzheimer's disease.Bioorganic & medicinal chemistry letters, , 10-01, Volume: 49, 2021
Progress and developments in tau aggregation inhibitors for Alzheimer disease.Journal of medicinal chemistry, , Jun-13, Volume: 56, Issue:11, 2013
Discovery and characterization of novel indole and 7-azaindole derivatives as inhibitors of β-amyloid-42 aggregation for the treatment of Alzheimer's disease.Bioorganic & medicinal chemistry letters, , 03-15, Volume: 27, Issue:6, 2017
Synthesis and structure-activity relationship of 2,6-disubstituted pyridine derivatives as inhibitors of β-amyloid-42 aggregation.Bioorganic & medicinal chemistry letters, , 07-15, Volume: 26, Issue:14, 2016
Novel anilinophthalimide derivatives as potential probes for beta-amyloid plaque in the brain.Bioorganic & medicinal chemistry, , Volume: 18, Issue:3, 2010
Radioiodinated flavones for in vivo imaging of beta-amyloid plaques in the brain.Journal of medicinal chemistry, , Nov-17, Volume: 48, Issue:23, 2005
Combined in Vitro Cell-Based/in Silico Screening of Naturally Occurring Flavonoids and Phenolic Compounds as Potential Anti-Alzheimer Drugs.Journal of natural products, , 02-24, Volume: 80, Issue:2, 2017
Progress and developments in tau aggregation inhibitors for Alzheimer disease.Journal of medicinal chemistry, , Jun-13, Volume: 56, Issue:11, 2013
Novel anilinophthalimide derivatives as potential probes for beta-amyloid plaque in the brain.Bioorganic & medicinal chemistry, , Volume: 18, Issue:3, 2010
18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Radioiodinated flavones for in vivo imaging of beta-amyloid plaques in the brain.Journal of medicinal chemistry, , Nov-17, Volume: 48, Issue:23, 2005
Near-Infrared Fluorescent Probes as Imaging and Theranostic Modalities for Amyloid-Beta and Tau Aggregates in Alzheimer's Disease.Journal of medicinal chemistry, , 07-14, Volume: 65, Issue:13, 2022
Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.Journal of medicinal chemistry, , Jun-19, Volume: 46, Issue:13, 2003
Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates.Journal of medicinal chemistry, , Jun-07, Volume: 44, Issue:12, 2001
Nodulisporiviridins A-H, Bioactive Viridins from Nodulisporium sp.Journal of natural products, , Jun-26, Volume: 78, Issue:6, 2015
Naturally occurring polyphenolic inhibitors of amyloid beta aggregation.Bioorganic & medicinal chemistry letters, , Jul-15, Volume: 24, Issue:14, 2014
Progress and developments in tau aggregation inhibitors for Alzheimer disease.Journal of medicinal chemistry, , Jun-13, Volume: 56, Issue:11, 2013
Combined in Vitro Cell-Based/in Silico Screening of Naturally Occurring Flavonoids and Phenolic Compounds as Potential Anti-Alzheimer Drugs.Journal of natural products, , 02-24, Volume: 80, Issue:2, 2017
Site-specific inhibitory mechanism for amyloid β42 aggregation by catechol-type flavonoids targeting the Lys residues.The Journal of biological chemistry, , Aug-09, Volume: 288, Issue:32, 2013
18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging.Journal of medicinal chemistry, , Oct-05, Volume: 49, Issue:20, 2006
Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates.Journal of medicinal chemistry, , Jun-07, Volume: 44, Issue:12, 2001
Combined in Vitro Cell-Based/in Silico Screening of Naturally Occurring Flavonoids and Phenolic Compounds as Potential Anti-Alzheimer Drugs.Journal of natural products, , 02-24, Volume: 80, Issue:2, 2017
Site-specific inhibitory mechanism for amyloid β42 aggregation by catechol-type flavonoids targeting the Lys residues.The Journal of biological chemistry, , Aug-09, Volume: 288, Issue:32, 2013
Structural insights into mechanisms for inhibiting amyloid β42 aggregation by non-catechol-type flavonoids.Bioorganic & medicinal chemistry, , Jan-15, Volume: 24, Issue:2, 2016
Site-specific inhibitory mechanism for amyloid β42 aggregation by catechol-type flavonoids targeting the Lys residues.The Journal of biological chemistry, , Aug-09, Volume: 288, Issue:32, 2013
Resveratrol-based compounds and neurodegeneration: Recent insight in multitarget therapy.European journal of medicinal chemistry, , Apr-05, Volume: 233, 2022
Novel deoxyvasicinone and tetrahydro-beta-carboline hybrids as inhibitors of acetylcholinesterase and amyloid beta aggregation.Bioorganic & medicinal chemistry letters, , 12-15, Volume: 30, Issue:24, 2020
[no title available]Bioorganic & medicinal chemistry, , 07-23, Volume: 26, Issue:12, 2018
Discovery of boron-containing compounds as Aβ aggregation inhibitors and antioxidants for the treatment of Alzheimer's disease.MedChemComm, , Nov-01, Volume: 9, Issue:11, 2018
Resveratrol-maltol hybrids as multi-target-directed agents for Alzheimer's disease.Bioorganic & medicinal chemistry, , 12-01, Volume: 26, Issue:22, 2018
Synthesis and evaluation of 1,2,3,4-tetrahydro-1-acridone analogues as potential dual inhibitors for amyloid-beta and tau aggregation.Bioorganic & medicinal chemistry, , 09-01, Volume: 26, Issue:16, 2018
2,4-Disubstituted quinazolines as amyloid-β aggregation inhibitors with dual cholinesterase inhibition and antioxidant properties: Development and structure-activity relationship (SAR) studies.European journal of medicinal chemistry, , Jan-27, Volume: 126, 2017
Synthesis and biological evaluation of deferiprone-resveratrol hybrids as antioxidants, AβEuropean journal of medicinal chemistry, , Feb-15, Volume: 127, 2017
Structure-Activity Relationship Studies of Isomeric 2,4-Diaminoquinazolines on β-Amyloid Aggregation Kinetics.ACS medicinal chemistry letters, , May-12, Volume: 7, Issue:5, 2016
Syntheses and evaluation of novel isoliquiritigenin derivatives as potential dual inhibitors for amyloid-beta aggregation and 5-lipoxygenase.European journal of medicinal chemistry, , Volume: 66, 2013
Design, synthesis, and evaluation of multitarget-directed resveratrol derivatives for the treatment of Alzheimer's disease.Journal of medicinal chemistry, , Jul-25, Volume: 56, Issue:14, 2013
Rationally designed divalent caffeic amides inhibit amyloid-β fibrillization, induce fibril dissociation, and ameliorate cytotoxicity.European journal of medicinal chemistry, , Oct-05, Volume: 158, 2018
Structure-activity relations of rosmarinic acid derivatives for the amyloid β aggregation inhibition and antioxidant properties.European journal of medicinal chemistry, , Sep-29, Volume: 138, 2017
Protective effects of caffeoylquinic acids on the aggregation and neurotoxicity of the 42-residue amyloid β-protein.Bioorganic & medicinal chemistry, , Oct-01, Volume: 20, Issue:19, 2012
Ferulic acid amide derivatives with varying inhibition of amyloid-β oligomerization and fibrillization.Bioorganic & medicinal chemistry, , 08-01, Volume: 43, 2021
[no title available]Bioorganic & medicinal chemistry, , 08-15, Volume: 44, 2021
Amyloid-β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review.European journal of medicinal chemistry, , Mar-15, Volume: 214, 2021
Novel deoxyvasicinone and tetrahydro-beta-carboline hybrids as inhibitors of acetylcholinesterase and amyloid beta aggregation.Bioorganic & medicinal chemistry letters, , 12-15, Volume: 30, Issue:24, 2020
Triazole derivatives as inhibitors of Alzheimer's disease: Current developments and structure-activity relationships.European journal of medicinal chemistry, , Oct-15, Volume: 180, 2019
Novel sarsasapogenin-triazolyl hybrids as potential anti-Alzheimer's agents: Design, synthesis and biological evaluation.European journal of medicinal chemistry, , May-10, Volume: 151, 2018
Discovery of boron-containing compounds as Aβ aggregation inhibitors and antioxidants for the treatment of Alzheimer's disease.MedChemComm, , Nov-01, Volume: 9, Issue:11, 2018
Resveratrol-maltol hybrids as multi-target-directed agents for Alzheimer's disease.Bioorganic & medicinal chemistry, , 12-01, Volume: 26, Issue:22, 2018
Curcumin derivatives and Aβ-fibrillar aggregates: An interactions' study for diagnostic/therapeutic purposes in neurodegenerative diseases.Bioorganic & medicinal chemistry, , 08-07, Volume: 26, Issue:14, 2018
Rationally designed divalent caffeic amides inhibit amyloid-β fibrillization, induce fibril dissociation, and ameliorate cytotoxicity.European journal of medicinal chemistry, , Oct-05, Volume: 158, 2018
The Essential Medicinal Chemistry of Curcumin.Journal of medicinal chemistry, , 03-09, Volume: 60, Issue:5, 2017
2,4-Disubstituted quinazolines as amyloid-β aggregation inhibitors with dual cholinesterase inhibition and antioxidant properties: Development and structure-activity relationship (SAR) studies.European journal of medicinal chemistry, , Jan-27, Volume: 126, 2017
Design, synthesis, in-silico and biological evaluation of novel donepezil derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease.European journal of medicinal chemistry, , Jan-05, Volume: 125, 2017
Combined in Vitro Cell-Based/in Silico Screening of Naturally Occurring Flavonoids and Phenolic Compounds as Potential Anti-Alzheimer Drugs.Journal of natural products, , 02-24, Volume: 80, Issue:2, 2017
Discovery and characterization of novel indole and 7-azaindole derivatives as inhibitors of β-amyloid-42 aggregation for the treatment of Alzheimer's disease.Bioorganic & medicinal chemistry letters, , 03-15, Volume: 27, Issue:6, 2017
Rational design, synthesis and biological screening of triazine-triazolopyrimidine hybrids as multitarget anti-Alzheimer agents.European journal of medicinal chemistry, , Aug-18, Volume: 136, 2017
Synthesis and biological evaluation of deferiprone-resveratrol hybrids as antioxidants, AβEuropean journal of medicinal chemistry, , Feb-15, Volume: 127, 2017
Neuritogenic activity of bi-functional bis-tryptoline triazole.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Synthesis and structure-activity relationship of 2,6-disubstituted pyridine derivatives as inhibitors of β-amyloid-42 aggregation.Bioorganic & medicinal chemistry letters, , 07-15, Volume: 26, Issue:14, 2016
Structure-Activity Relationship Studies of Isomeric 2,4-Diaminoquinazolines on β-Amyloid Aggregation Kinetics.ACS medicinal chemistry letters, , May-12, Volume: 7, Issue:5, 2016
Design, synthesis and evaluation of 4-dimethylamine flavonoid derivatives as potential multifunctional anti-Alzheimer agents.European journal of medicinal chemistry, , Oct-21, Volume: 122, 2016
Design and synthesis of curcumin derivatives as tau and amyloid β dual aggregation inhibitors.Bioorganic & medicinal chemistry letters, , 10-15, Volume: 26, Issue:20, 2016
Design, synthesis and evaluation of novel indandione derivatives as multifunctional agents with cholinesterase inhibition, anti-β-amyloid aggregation, antioxidant and neuroprotection properties against Alzheimer's disease.Bioorganic & medicinal chemistry, , 08-15, Volume: 24, Issue:16, 2016
Design and discovery of Novel Thiazole acetamide derivatives as anticholinesterase agent for possible role in the management of Alzheimer's.Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 26, Issue:3, 2016
Progress and developments in tau aggregation inhibitors for Alzheimer disease.Journal of medicinal chemistry, , Jun-13, Volume: 56, Issue:11, 2013
Contributions of academic laboratories to the discovery and development of chemical biology tools.Journal of medicinal chemistry, , Sep-26, Volume: 56, Issue:18, 2013
The β-Amyloid Hypothesis in Alzheimer's Disease: Seeing Is Believing.ACS medicinal chemistry letters, , Apr-12, Volume: 3, Issue:4, 2012
A Novel (18)F-Labeled Imidazo[2,1-b]benzothiazole (IBT) for High-Contrast PET Imaging of β-Amyloid Plaques.ACS medicinal chemistry letters, , Sep-08, Volume: 2, Issue:9, 2011
Synthesis and evaluation of two 18F-labeled imidazo[1,2-a]pyridine analogues as potential agents for imaging beta-amyloid in Alzheimer's disease.Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 16, Issue:11, 2006
Neuritogenic activity of bi-functional bis-tryptoline triazole.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Combined in Vitro Cell-Based/in Silico Screening of Naturally Occurring Flavonoids and Phenolic Compounds as Potential Anti-Alzheimer Drugs.Journal of natural products, , 02-24, Volume: 80, Issue:2, 2017
Structural insights into mechanisms for inhibiting amyloid β42 aggregation by non-catechol-type flavonoids.Bioorganic & medicinal chemistry, , Jan-15, Volume: 24, Issue:2, 2016
Site-specific inhibitory mechanism for amyloid β42 aggregation by catechol-type flavonoids targeting the Lys residues.The Journal of biological chemistry, , Aug-09, Volume: 288, Issue:32, 2013
Naturally occurring biflavonoids with amyloid β aggregation inhibitory activity for development of anti-Alzheimer agents.Bioorganic & medicinal chemistry letters, , 08-01, Volume: 29, Issue:15, 2019
Combined in Vitro Cell-Based/in Silico Screening of Naturally Occurring Flavonoids and Phenolic Compounds as Potential Anti-Alzheimer Drugs.Journal of natural products, , 02-24, Volume: 80, Issue:2, 2017
Combined in Vitro Cell-Based/in Silico Screening of Naturally Occurring Flavonoids and Phenolic Compounds as Potential Anti-Alzheimer Drugs.Journal of natural products, , 02-24, Volume: 80, Issue:2, 2017
Structural insights into mechanisms for inhibiting amyloid β42 aggregation by non-catechol-type flavonoids.Bioorganic & medicinal chemistry, , Jan-15, Volume: 24, Issue:2, 2016
Site-specific inhibitory mechanism for amyloid β42 aggregation by catechol-type flavonoids targeting the Lys residues.The Journal of biological chemistry, , Aug-09, Volume: 288, Issue:32, 2013
Structural insights into mechanisms for inhibiting amyloid β42 aggregation by non-catechol-type flavonoids.Bioorganic & medicinal chemistry, , Jan-15, Volume: 24, Issue:2, 2016
Site-specific inhibitory mechanism for amyloid β42 aggregation by catechol-type flavonoids targeting the Lys residues.The Journal of biological chemistry, , Aug-09, Volume: 288, Issue:32, 2013
Structural insights into mechanisms for inhibiting amyloid β42 aggregation by non-catechol-type flavonoids.Bioorganic & medicinal chemistry, , Jan-15, Volume: 24, Issue:2, 2016
Site-specific inhibitory mechanism for amyloid β42 aggregation by catechol-type flavonoids targeting the Lys residues.The Journal of biological chemistry, , Aug-09, Volume: 288, Issue:32, 2013
Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease.European journal of medicinal chemistry, , Apr-15, Volume: 192, 2020
Structural insights into mechanisms for inhibiting amyloid β42 aggregation by non-catechol-type flavonoids.Bioorganic & medicinal chemistry, , Jan-15, Volume: 24, Issue:2, 2016
Site-specific inhibitory mechanism for amyloid β42 aggregation by catechol-type flavonoids targeting the Lys residues.The Journal of biological chemistry, , Aug-09, Volume: 288, Issue:32, 2013
Inhibition of BACE1 and Amyloid-β Aggregation by Meroterpenoids from the Mushroom Journal of natural products, , 06-25, Volume: 84, Issue:6, 2021
Isolation of three new meroterpenoids and seven known compounds from Albatrellus yasudae and their Aβ-aggregation inhibitory activity.Bioorganic & medicinal chemistry letters, , 01-15, Volume: 30, Issue:2, 2020
Naturally occurring biflavonoids with amyloid β aggregation inhibitory activity for development of anti-Alzheimer agents.Bioorganic & medicinal chemistry letters, , 08-01, Volume: 29, Issue:15, 2019
Combined in Vitro Cell-Based/in Silico Screening of Naturally Occurring Flavonoids and Phenolic Compounds as Potential Anti-Alzheimer Drugs.Journal of natural products, , 02-24, Volume: 80, Issue:2, 2017
Structural insights into mechanisms for inhibiting amyloid β42 aggregation by non-catechol-type flavonoids.Bioorganic & medicinal chemistry, , Jan-15, Volume: 24, Issue:2, 2016
Development of dual targeting inhibitors against aggregations of amyloid-β and tau protein.European journal of medicinal chemistry, , Oct-06, Volume: 85, 2014
Site-specific inhibitory mechanism for amyloid β42 aggregation by catechol-type flavonoids targeting the Lys residues.The Journal of biological chemistry, , Aug-09, Volume: 288, Issue:32, 2013
Inhibition of BACE1 and Amyloid-β Aggregation by Meroterpenoids from the Mushroom Journal of natural products, , 06-25, Volume: 84, Issue:6, 2021
Isolation of three new meroterpenoids and seven known compounds from Albatrellus yasudae and their Aβ-aggregation inhibitory activity.Bioorganic & medicinal chemistry letters, , 01-15, Volume: 30, Issue:2, 2020
18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.Journal of medicinal chemistry, , Jun-19, Volume: 46, Issue:13, 2003
Alzheimer's disease: Updated multi-targets therapeutics are in clinical and in progress.European journal of medicinal chemistry, , Aug-05, Volume: 238, 2022
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.Bioorganic & medicinal chemistry, , 12-15, Volume: 26, Issue:23-24, 2018
Quinones bearing non-steroidal anti-inflammatory fragments as multitarget ligands for Alzheimer's disease.Bioorganic & medicinal chemistry letters, , Dec-01, Volume: 23, Issue:23, 2013
Preliminary evaluation of fluoro-pegylated benzyloxybenzenes for quantification of β-amyloid plaques by positron emission tomography.European journal of medicinal chemistry, , Nov-02, Volume: 104, 2015
Radioiodinated benzyloxybenzene derivatives: a class of flexible ligands target to β-amyloid plaques in Alzheimer's brains.Journal of medicinal chemistry, , Jul-24, Volume: 57, Issue:14, 2014
Structure-Activity Relationships and in Vivo Evaluation of Quinoxaline Derivatives for PET Imaging of β-Amyloid Plaques.ACS medicinal chemistry letters, , Jul-11, Volume: 4, Issue:7, 2013
Synthesis and biological evaluation of 18F-labled 2-phenylindole derivatives as PET imaging probes for β-amyloid plaques.Bioorganic & medicinal chemistry, , Jul-01, Volume: 21, Issue:13, 2013
Synthesis and biological evaluation of radioiodinated quinacrine-based derivatives for SPECT imaging of Aβ plaques.European journal of medicinal chemistry, , Volume: 60, 2013
Diphenylpropynone derivatives as probes for imaging β-amyloid plaques in Alzheimer's brains.Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 21, Issue:1, 2011
Novel anilinophthalimide derivatives as potential probes for beta-amyloid plaque in the brain.Bioorganic & medicinal chemistry, , Volume: 18, Issue:3, 2010
18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Synthesis and structure-affinity relationships of new 4-(6-iodo-H-imidazo[1,2-a]pyridin-2-yl)-N-dimethylbenzeneamine derivatives as ligands for human beta-amyloid plaques.Journal of medicinal chemistry, , Sep-20, Volume: 50, Issue:19, 2007
Synthesis and evaluation of two 18F-labeled imidazo[1,2-a]pyridine analogues as potential agents for imaging beta-amyloid in Alzheimer's disease.Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 16, Issue:11, 2006
Structure-activity relationship of imidazo[1,2-a]pyridines as ligands for detecting beta-amyloid plaques in the brain.Journal of medicinal chemistry, , Jan-16, Volume: 46, Issue:2, 2003
Preliminary evaluation of fluoro-pegylated benzyloxybenzenes for quantification of β-amyloid plaques by positron emission tomography.European journal of medicinal chemistry, , Nov-02, Volume: 104, 2015
Radioiodinated benzyloxybenzene derivatives: a class of flexible ligands target to β-amyloid plaques in Alzheimer's brains.Journal of medicinal chemistry, , Jul-24, Volume: 57, Issue:14, 2014
Synthesis and evaluation of pyridylbenzofuran, pyridylbenzothiazole and pyridylbenzoxazole derivatives as ¹⁸F-PET imaging agents for β-amyloid plaques.Bioorganic & medicinal chemistry letters, , Jul-01, Volume: 22, Issue:13, 2012
Synthesis and evaluation of 11C-labeled imidazo[2,1-b]benzothiazoles (IBTs) as PET tracers for imaging β-amyloid plaques in Alzheimer's disease.Journal of medicinal chemistry, , Feb-24, Volume: 54, Issue:4, 2011
Novel anilinophthalimide derivatives as potential probes for beta-amyloid plaque in the brain.Bioorganic & medicinal chemistry, , Volume: 18, Issue:3, 2010
18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.Journal of medicinal chemistry, , Jun-19, Volume: 46, Issue:13, 2003
The β-Amyloid Hypothesis in Alzheimer's Disease: Seeing Is Believing.ACS medicinal chemistry letters, , Apr-12, Volume: 3, Issue:4, 2012
Synthesis and evaluation of ¹⁸F-labeled styryltriazole and resveratrol derivatives for β-amyloid plaque imaging.Journal of medicinal chemistry, , Jan-26, Volume: 55, Issue:2, 2012
The β-Amyloid Hypothesis in Alzheimer's Disease: Seeing Is Believing.ACS medicinal chemistry letters, , Apr-12, Volume: 3, Issue:4, 2012
Synthesis and evaluation of ¹⁸F-labeled styryltriazole and resveratrol derivatives for β-amyloid plaque imaging.Journal of medicinal chemistry, , Jan-26, Volume: 55, Issue:2, 2012
18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Enables
This protein enables 13 target(s):
Target | Category | Definition |
RNA polymerase II cis-regulatory region sequence-specific DNA binding | molecular function | Binding to a specific upstream regulatory DNA sequence (transcription factor recognition sequence or binding site) located in cis relative to the transcription start site (i.e., on the same strand of DNA) of a gene transcribed by RNA polymerase II. [GOC:txnOH-2018] |
DNA binding | molecular function | Any molecular function by which a gene product interacts selectively and non-covalently with DNA (deoxyribonucleic acid). [GOC:dph, GOC:jl, GOC:tb, GOC:vw] |
serine-type endopeptidase inhibitor activity | molecular function | Binds to and stops, prevents or reduces the activity of a serine-type endopeptidase. [GOC:ai] |
signaling receptor binding | molecular function | Binding to one or more specific sites on a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function. [GOC:bf, GOC:ceb, ISBN:0198506732] |
protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
heparin binding | molecular function | Binding to heparin, a member of a group of glycosaminoglycans found mainly as an intracellular component of mast cells and which consist predominantly of alternating alpha-(1->4)-linked D-galactose and N-acetyl-D-glucosamine-6-sulfate residues. [GOC:jl, ISBN:0198506732] |
enzyme binding | molecular function | Binding to an enzyme, a protein with catalytic activity. [GOC:jl] |
identical protein binding | molecular function | Binding to an identical protein or proteins. [GOC:jl] |
transition metal ion binding | molecular function | Binding to a transition metal ions; a transition metal is an element whose atom has an incomplete d-subshell of extranuclear electrons, or which gives rise to a cation or cations with an incomplete d-subshell. Transition metals often have more than one valency state. Biologically relevant transition metals include vanadium, manganese, iron, copper, cobalt, nickel, molybdenum and silver. [ISBN:0198506732] |
receptor ligand activity | molecular function | The activity of a gene product that interacts with a receptor to effect a change in the activity of the receptor. Ligands may be produced by the same, or different, cell that expresses the receptor. Ligands may diffuse extracellularly from their point of origin to the receiving cell, or remain attached to an adjacent cell surface (e.g. Notch ligands). [GOC:kv, GOC:molecular_function_refactoring, GOC:pdt] |
PTB domain binding | molecular function | Binding to a phosphotyrosine-binding (PTB) Binding to a phosphotyrosine-bindin domain. [Pfam:PF02174, PMID:15924411] |
protein serine/threonine kinase binding | molecular function | Binding to a protein serine/threonine kinase. [GOC:krc, GOC:sl, PMID:28608965] |
signaling receptor activator activity | molecular function | The function of interacting (directly or indirectly) with receptors such that the proportion of receptors in the active form is increased. [GOC:ceb] |
Located In
This protein is located in 39 target(s):
Target | Category | Definition |
extracellular region | cellular component | The space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane. This term covers the host cell environment outside an intracellular parasite. [GOC:go_curators] |
extracellular space | cellular component | That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid. [ISBN:0198547684] |
nuclear envelope lumen | cellular component | The region between the two lipid bilayers of the nuclear envelope; 20-40 nm wide. [GOC:ai] |
cytoplasm | cellular component | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. [ISBN:0198547684] |
mitochondrial inner membrane | cellular component | The inner, i.e. lumen-facing, lipid bilayer of the mitochondrial envelope. It is highly folded to form cristae. [GOC:ai] |
endosome | cellular component | A vacuole to which materials ingested by endocytosis are delivered. [ISBN:0198506732, PMID:19696797] |
early endosome | cellular component | A membrane-bounded organelle that receives incoming material from primary endocytic vesicles that have been generated by clathrin-dependent and clathrin-independent endocytosis; vesicles fuse with the early endosome to deliver cargo for sorting into recycling or degradation pathways. [GOC:mah, NIF_Subcellular:nlx_subcell_20090701, PMID:19696797] |
endoplasmic reticulum | cellular component | The irregular network of unit membranes, visible only by electron microscopy, that occurs in the cytoplasm of many eukaryotic cells. The membranes form a complex meshwork of tubular channels, which are often expanded into slitlike cavities called cisternae. The ER takes two forms, rough (or granular), with ribosomes adhering to the outer surface, and smooth (with no ribosomes attached). [ISBN:0198506732] |
endoplasmic reticulum lumen | cellular component | The volume enclosed by the membranes of the endoplasmic reticulum. [ISBN:0198547684] |
smooth endoplasmic reticulum | cellular component | The smooth endoplasmic reticulum (smooth ER or SER) has no ribosomes attached to it. The smooth ER is the recipient of the proteins synthesized in the rough ER. Those proteins to be exported are passed to the Golgi complex, the resident proteins are returned to the rough ER and the lysosomal proteins after phosphorylation of their mannose residues are passed to the lysosomes. Glycosylation of the glycoproteins also continues. The smooth ER is the site of synthesis of lipids, including the phospholipids. The membranes of the smooth ER also contain enzymes that catalyze a series of reactions to detoxify both lipid-soluble drugs and harmful products of metabolism. Large quantities of certain compounds such as phenobarbital cause an increase in the amount of the smooth ER. [ISBN:0198506732] |
Golgi apparatus | cellular component | A membrane-bound cytoplasmic organelle of the endomembrane system that further processes the core oligosaccharides (e.g. N-glycans) added to proteins in the endoplasmic reticulum and packages them into membrane-bound vesicles. The Golgi apparatus operates at the intersection of the secretory, lysosomal, and endocytic pathways. [ISBN:0198506732] |
Golgi lumen | cellular component | The volume enclosed by the membranes of any cisterna or subcompartment of the Golgi apparatus, including the cis- and trans-Golgi networks. [GOC:mah] |
Golgi-associated vesicle | cellular component | Any vesicle associated with the Golgi complex and involved in mediating transport within the Golgi or between the Golgi and other parts of the cell. [GOC:mah] |
cytosol | cellular component | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. [GOC:hjd, GOC:jl] |
plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
clathrin-coated pit | cellular component | A part of the endomembrane system in the form of an invagination of a membrane upon which a clathrin coat forms, and that can be converted by vesicle budding into a clathrin-coated vesicle. Coated pits form on the plasma membrane, where they are involved in receptor-mediated selective transport of many proteins and other macromolecules across the cell membrane, in the trans-Golgi network, and on some endosomes. [GOC:mah, ISBN:0198506732, NIF_Subcellular:sao1969557946, PMID:10559856, PMID:17284835] |
cell-cell junction | cellular component | A cell junction that forms a connection between two or more cells of an organism; excludes direct cytoplasmic intercellular bridges, such as ring canals in insects. [GOC:aruk, GOC:bc, GOC:dgh, GOC:hb, GOC:mah, PMID:21422226, PMID:28096264] |
synaptic vesicle | cellular component | A secretory organelle, typically 50 nm in diameter, of presynaptic nerve terminals; accumulates in high concentrations of neurotransmitters and secretes these into the synaptic cleft by fusion with the 'active zone' of the presynaptic plasma membrane. [PMID:10099709, PMID:12563290] |
cell surface | cellular component | The external part of the cell wall and/or plasma membrane. [GOC:jl, GOC:mtg_sensu, GOC:sm] |
membrane | cellular component | A lipid bilayer along with all the proteins and protein complexes embedded in it and attached to it. [GOC:dos, GOC:mah, ISBN:0815316194] |
COPII-coated ER to Golgi transport vesicle | cellular component | A vesicle with a coat formed of the COPII coat complex proteins. The COPII coat complex is formed by the Sec23p/Sec24p and the Sec13p/Sec31p heterodimers. COPII-associated vesicles transport proteins from the rough endoplasmic reticulum to the Golgi apparatus (anterograde transport). [PMID:11252894, PMID:17499046, PMID:22160157, PMID:8004676, Wikipedia:COPII] |
axon | cellular component | The long process of a neuron that conducts nerve impulses, usually away from the cell body to the terminals and varicosities, which are sites of storage and release of neurotransmitter. [GOC:nln, ISBN:0198506732] |
growth cone | cellular component | The migrating motile tip of a growing neuron projection, where actin accumulates, and the actin cytoskeleton is the most dynamic. [GOC:aruk, GOC:bc, ISBN:0815316194, PMID:10082468] |
platelet alpha granule lumen | cellular component | The volume enclosed by the membrane of the platelet alpha granule. [GOC:mah, PMID:8467233] |
neuromuscular junction | cellular component | The junction between the axon of a motor neuron and a muscle fiber. In response to the arrival of action potentials, the presynaptic button releases molecules of neurotransmitters into the synaptic cleft. These diffuse across the cleft and transmit the signal to the postsynaptic membrane of the muscle fiber, leading to a change in post-synaptic potential. [GOC:nln] |
endosome lumen | cellular component | The volume enclosed by the membrane of an endosome. [GOC:mah] |
trans-Golgi network membrane | cellular component | The lipid bilayer surrounding any of the compartments that make up the trans-Golgi network. [GOC:mah] |
ciliary rootlet | cellular component | A cytoskeleton-like structure, originating from the basal body at the proximal end of a cilium, and extending proximally toward the cell nucleus. Rootlets are typically 80-100 nm in diameter and contain cross striae distributed at regular intervals of approximately 55-70 nm. [GOC:cilia, PMID:12427867] |
dendritic spine | cellular component | A small, membranous protrusion from a dendrite that forms a postsynaptic compartment, typically receiving input from a single presynapse. They function as partially isolated biochemical and an electrical compartments. Spine morphology is variable:they can be thin, stubby, mushroom, or branched, with a continuum of intermediate morphologies. They typically terminate in a bulb shape, linked to the dendritic shaft by a restriction. Spine remodeling is though to be involved in synaptic plasticity. [GOC:nln] |
dendritic shaft | cellular component | Cylindric portion of the dendrite, directly stemming from the perikaryon, and carrying the dendritic spines. [GOC:nln] |
perikaryon | cellular component | The portion of the cell soma (neuronal cell body) that excludes the nucleus. [GOC:jl] |
membrane raft | cellular component | Any of the small (10-200 nm), heterogeneous, highly dynamic, sterol- and sphingolipid-enriched membrane domains that compartmentalize cellular processes. Small rafts can sometimes be stabilized to form larger platforms through protein-protein and protein-lipid interactions. [PMID:16645198, PMID:20044567] |
apical part of cell | cellular component | The region of a polarized cell that forms a tip or is distal to a base. For example, in a polarized epithelial cell, the apical region has an exposed surface and lies opposite to the basal lamina that separates the epithelium from other tissue. [GOC:mah, ISBN:0815316194] |
synapse | cellular component | The junction between an axon of one neuron and a dendrite of another neuron, a muscle fiber or a glial cell. As the axon approaches the synapse it enlarges into a specialized structure, the presynaptic terminal bouton, which contains mitochondria and synaptic vesicles. At the tip of the terminal bouton is the presynaptic membrane; facing it, and separated from it by a minute cleft (the synaptic cleft) is a specialized area of membrane on the receiving cell, known as the postsynaptic membrane. In response to the arrival of nerve impulses, the presynaptic terminal bouton secretes molecules of neurotransmitters into the synaptic cleft. These diffuse across the cleft and transmit the signal to the postsynaptic membrane. [GOC:aruk, ISBN:0198506732, PMID:24619342, PMID:29383328, PMID:31998110] |
perinuclear region of cytoplasm | cellular component | Cytoplasm situated near, or occurring around, the nucleus. [GOC:jid] |
presynaptic active zone | cellular component | A specialized region of the plasma membrane and cell cortex of a presynaptic neuron; encompasses a region of the plasma membrane where synaptic vesicles dock and fuse, and a specialized cortical cytoskeletal matrix. [GOC:dh, GOC:dl, GOC:ef, GOC:jid, GOC:pr, PMID:3152289] |
spindle midzone | cellular component | The area in the center of the spindle where the spindle microtubules from opposite poles overlap. [GOC:ai, PMID:15296749] |
recycling endosome | cellular component | An organelle consisting of a network of tubules that functions in targeting molecules, such as receptors transporters and lipids, to the plasma membrane. [GOC:dph, GOC:jid, GOC:kmv, GOC:rph, PMID:10930469, PMID:15601896, PMID:16246101, PMID:21556374, PMID:21562044] |
extracellular exosome | cellular component | A vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane. Extracellular exosomes, also simply called exosomes, have a diameter of about 40-100 nm. [GOC:BHF, GOC:mah, GOC:vesicles, PMID:15908444, PMID:17641064, PMID:19442504, PMID:19498381, PMID:22418571, PMID:24009894] |
Active In
This protein is active in 7 target(s):
Target | Category | Definition |
extracellular space | cellular component | That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid. [ISBN:0198547684] |
dendrite | cellular component | A neuron projection that has a short, tapering, morphology. Dendrites receive and integrate signals from other neurons or from sensory stimuli, and conduct nerve impulses towards the axon or the cell body. In most neurons, the impulse is conveyed from dendrites to axon via the cell body, but in some types of unipolar neuron, the impulse does not travel via the cell body. [GOC:aruk, GOC:bc, GOC:dos, GOC:mah, GOC:nln, ISBN:0198506732] |
early endosome | cellular component | A membrane-bounded organelle that receives incoming material from primary endocytic vesicles that have been generated by clathrin-dependent and clathrin-independent endocytosis; vesicles fuse with the early endosome to deliver cargo for sorting into recycling or degradation pathways. [GOC:mah, NIF_Subcellular:nlx_subcell_20090701, PMID:19696797] |
membrane raft | cellular component | Any of the small (10-200 nm), heterogeneous, highly dynamic, sterol- and sphingolipid-enriched membrane domains that compartmentalize cellular processes. Small rafts can sometimes be stabilized to form larger platforms through protein-protein and protein-lipid interactions. [PMID:16645198, PMID:20044567] |
cell surface | cellular component | The external part of the cell wall and/or plasma membrane. [GOC:jl, GOC:mtg_sensu, GOC:sm] |
Golgi apparatus | cellular component | A membrane-bound cytoplasmic organelle of the endomembrane system that further processes the core oligosaccharides (e.g. N-glycans) added to proteins in the endoplasmic reticulum and packages them into membrane-bound vesicles. The Golgi apparatus operates at the intersection of the secretory, lysosomal, and endocytic pathways. [ISBN:0198506732] |
plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
Part Of
This protein is part of 1 target(s):
Target | Category | Definition |
receptor complex | cellular component | Any protein complex that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function. [GOC:go_curators] |
Involved In
This protein is involved in 78 target(s):
Target | Category | Definition |
G2/M transition of mitotic cell cycle | biological process | The mitotic cell cycle transition by which a cell in G2 commits to M phase. The process begins when the kinase activity of M cyclin/CDK complex reaches a threshold high enough for the cell cycle to proceed. This is accomplished by activating a positive feedback loop that results in the accumulation of unphosphorylated and active M cyclin/CDK complex. [GOC:mtg_cell_cycle] |
microglial cell activation | biological process | The change in morphology and behavior of a microglial cell resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor. [GOC:mgi_curators, PMID:10626665, PMID:10695728, PMID:12580336, PMID:9893949] |
positive regulation of protein phosphorylation | biological process | Any process that activates or increases the frequency, rate or extent of addition of phosphate groups to amino acids within a protein. [GOC:hjd] |
suckling behavior | biological process | Specific behavior of a newborn or infant mammal that results in the derivation of nourishment from the breast. [GOC:dph, GOC:pr] |
astrocyte activation involved in immune response | biological process | A change in the morphology or behavior of an astrocyte resulting from exposure to an activating factor such as a cellular or soluble ligand, leading to the initiation or perpetuation of an immune response. [GOC:add, PMID:11138785] |
regulation of translation | biological process | Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of proteins by the translation of mRNA or circRNA. [GOC:isa_complete] |
protein phosphorylation | biological process | The process of introducing a phosphate group on to a protein. [GOC:hb] |
intracellular copper ion homeostasis | biological process | A homeostatic process involved in the maintenance of a steady state level of copper ions within a cell. [GOC:ai, GOC:mah] |
endocytosis | biological process | A vesicle-mediated transport process in which cells take up external materials or membrane constituents by the invagination of a part of the plasma membrane to form a new membrane-bounded vesicle. [GOC:mah, ISBN:0198506732, ISBN:0716731363, Wikipedia:Endocytosis] |
response to oxidative stress | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of oxidative stress, a state often resulting from exposure to high levels of reactive oxygen species, e.g. superoxide anions, hydrogen peroxide (H2O2), and hydroxyl radicals. [GOC:jl, PMID:12115731] |
cell adhesion | biological process | The attachment of a cell, either to another cell or to an underlying substrate such as the extracellular matrix, via cell adhesion molecules. [GOC:hb, GOC:pf] |
regulation of epidermal growth factor-activated receptor activity | biological process | Any process that modulates the frequency, rate or extent of EGF-activated receptor activity. [GOC:dph, GOC:go_curators] |
Notch signaling pathway | biological process | The series of molecular signals initiated by an extracellular ligand binding to the receptor Notch on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. [GOC:go_curators, GOC:signaling] |
axonogenesis | biological process | De novo generation of a long process of a neuron, including the terminal branched region. Refers to the morphogenesis or creation of shape or form of the developing axon, which carries efferent (outgoing) action potentials from the cell body towards target cells. [GOC:dph, GOC:jid, GOC:pg, GOC:pr, ISBN:0198506732] |
learning or memory | biological process | The acquisition and processing of information and/or the storage and retrieval of this information over time. [GOC:jid, PMID:8938125] |
learning | biological process | Any process in an organism in which a relatively long-lasting adaptive behavioral change occurs as the result of experience. [ISBN:0582227089, ISBN:0721662544] |
mating behavior | biological process | The behavioral interactions between organisms for the purpose of mating, or sexual reproduction resulting in the formation of zygotes. [GOC:ai, GOC:dph] |
locomotory behavior | biological process | The specific movement from place to place of an organism in response to external or internal stimuli. Locomotion of a whole organism in a manner dependent upon some combination of that organism's internal state and external conditions. [GOC:dph] |
axo-dendritic transport | biological process | The directed movement of organelles or molecules along microtubules in neuron projections. [ISBN:0815316194] |
cholesterol metabolic process | biological process | The chemical reactions and pathways involving cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones. It is a component of the plasma membrane lipid bilayer and of plasma lipoproteins and can be found in all animal tissues. [ISBN:0198506732] |
negative regulation of cell population proliferation | biological process | Any process that stops, prevents or reduces the rate or extent of cell proliferation. [GOC:go_curators] |
adult locomotory behavior | biological process | Locomotory behavior in a fully developed and mature organism. [GOC:ai] |
visual learning | biological process | Any process in an organism in which a change in behavior of an individual occurs in response to repeated exposure to a visual cue. [GOC:jid, ISBN:0582227089] |
regulation of gene expression | biological process | Any process that modulates the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product (protein or RNA). [GOC:txnOH-2018] |
positive regulation of gene expression | biological process | Any process that increases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product (protein or RNA). [GOC:txnOH-2018] |
negative regulation of gene expression | biological process | Any process that decreases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product (protein or RNA). [GOC:txnOH-2018] |
positive regulation of peptidyl-threonine phosphorylation | biological process | Any process that increases the frequency, rate or extent of peptidyl-threonine phosphorylation. Peptidyl-threonine phosphorylation is the phosphorylation of peptidyl-threonine to form peptidyl-O-phospho-L-threonine. [GOC:dph, GOC:tb] |
positive regulation of G2/M transition of mitotic cell cycle | biological process | Any signaling pathway that activates or increases the activity of a cell cycle cyclin-dependent protein kinase to modulate the switch from G2 phase to M phase of the mitotic cell cycle. [GOC:dph, GOC:mtg_cell_cycle, GOC:tb] |
microglia development | biological process | The process aimed at the progression of a microglial cell over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell. [GOC:dgh, GOC:ef] |
axon midline choice point recognition | biological process | The recognition of molecules at the central nervous system midline choice point by an axon growth cone; this choice point determines whether the growth cone will cross the midline. [PMID:11376484] |
neuron remodeling | biological process | The developmentally regulated remodeling of neuronal projections such as pruning to eliminate the extra dendrites and axons projections set up in early stages of nervous system development. [GOC:hb] |
dendrite development | biological process | The process whose specific outcome is the progression of the dendrite over time, from its formation to the mature structure. [GOC:aruk, GOC:bc, GOC:jl, ISBN:0198506732, PMID:22683681] |
regulation of Wnt signaling pathway | biological process | Any process that modulates the frequency, rate or extent of the activity of the Wnt signal transduction pathway. [GOC:dph, GOC:mah, GOC:tb] |
extracellular matrix organization | biological process | A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of an extracellular matrix. [GOC:mah] |
forebrain development | biological process | The process whose specific outcome is the progression of the forebrain over time, from its formation to the mature structure. The forebrain is the anterior of the three primary divisions of the developing chordate brain or the corresponding part of the adult brain (in vertebrates, includes especially the cerebral hemispheres, the thalamus, and the hypothalamus and especially in higher vertebrates is the main control center for sensory and associative information processing, visceral functions, and voluntary motor functions). [http://www2.merriam-webster.com/cgi-bin/mwmednlm?book=Medical&va=forebrain] |
neuron projection development | biological process | The process whose specific outcome is the progression of a neuron projection over time, from its formation to the mature structure. A neuron projection is any process extending from a neural cell, such as axons or dendrites (collectively called neurites). [GOC:mah] |
positive regulation of chemokine production | biological process | Any process that activates or increases the frequency, rate, or extent of chemokine production. [GOC:mah] |
positive regulation of interleukin-1 beta production | biological process | Any process that activates or increases the frequency, rate, or extent of interleukin-1 beta production. [GOC:mah] |
positive regulation of interleukin-6 production | biological process | Any process that activates or increases the frequency, rate, or extent of interleukin-6 production. [GOC:mah] |
positive regulation of tumor necrosis factor production | biological process | Any process that activates or increases the frequency, rate or extent of tumor necrosis factor production. [GO_REF:0000058, GOC:TermGenie, PMID:10891884, PMID:15560120] |
positive regulation of peptidyl-serine phosphorylation | biological process | Any process that activates or increases the frequency, rate or extent of the phosphorylation of peptidyl-serine. [GOC:mah] |
ionotropic glutamate receptor signaling pathway | biological process | The series of molecular signals initiated by glutamate binding to a glutamate receptor on the surface of the target cell, followed by the movement of ions through a channel in the receptor complex, and ending with the regulation of a downstream cellular process, e.g. transcription. [GOC:signaling, ISBN:0198506732] |
regulation of multicellular organism growth | biological process | Any process that modulates the frequency, rate or extent of growth of the body of an organism so that it reaches its usual body size. [GOC:dph, GOC:ems, GOC:tb] |
negative regulation of neuron differentiation | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of neuron differentiation. [GOC:go_curators] |
positive regulation of glycolytic process | biological process | Any process that activates or increases the frequency, rate or extent of glycolysis. [GOC:go_curators] |
positive regulation of mitotic cell cycle | biological process | Any process that activates or increases the rate or extent of progression through the mitotic cell cycle. [GOC:dph, GOC:go_curators, GOC:tb] |
positive regulation of transcription by RNA polymerase II | biological process | Any process that activates or increases the frequency, rate or extent of transcription from an RNA polymerase II promoter. [GOC:go_curators, GOC:txnOH] |
positive regulation of JNK cascade | biological process | Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the JNK cascade. [GOC:bf] |
astrocyte activation | biological process | A change in morphology and behavior of an astrocyte resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor. [GOC:mgi_curators, PMID:10526094, PMID:10695728, PMID:12529254, PMID:12580336, PMID:9585813] |
regulation of long-term neuronal synaptic plasticity | biological process | A process that modulates long-term neuronal synaptic plasticity, the ability of neuronal synapses to change long-term as circumstances require. Long-term neuronal synaptic plasticity generally involves increase or decrease in actual synapse numbers. [GOC:jid, PMID:11891290] |
collateral sprouting in absence of injury | biological process | The process in which outgrowths develop from the axons of intact undamaged neurons. [GOC:dgh, GOC:dph, GOC:jid, GOC:lm] |
positive regulation of inflammatory response | biological process | Any process that activates or increases the frequency, rate or extent of the inflammatory response. [GOC:ai] |
regulation of peptidyl-tyrosine phosphorylation | biological process | Any process that modulates the frequency, rate or extent of the phosphorylation of peptidyl-tyrosine. [GOC:ai] |
regulation of synapse structure or activity | biological process | Any process that modulates the physical form or the activity of a synapse, the junction between a neuron and a target (neuron, muscle, or secretory cell). [GOC:ai] |
synapse organization | biological process | A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a synapse, the junction between a neuron and a target (neuron, muscle, or secretory cell). [GOC:ai, GOC:pr] |
positive regulation of calcium-mediated signaling | biological process | Any process that activates or increases the frequency, rate or extent of calcium-mediated signaling. [GOC:ai] |
neuromuscular process controlling balance | biological process | Any process that an organism uses to control its balance, the orientation of the organism (or the head of the organism) in relation to the source of gravity. In humans and animals, balance is perceived through visual cues, the labyrinth system of the inner ears and information from skin pressure receptors and muscle and joint receptors. [GOC:ai, GOC:dph] |
synaptic assembly at neuromuscular junction | biological process | The assembly of a synapse at a neuromuscular junction. [PMID:20215342] |
positive regulation of protein metabolic process | biological process | Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving a protein. [GOC:ai] |
neuron apoptotic process | biological process | Any apoptotic process in a neuron, the basic cellular unit of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the nervous system. [CL:0000540, GOC:mtg_apoptosis] |
smooth endoplasmic reticulum calcium ion homeostasis | biological process | Any process involved in the maintenance of an internal steady state of calcium ions within the smooth endoplasmic reticulum of a cell or between the smooth endoplasmic reticulum and its surroundings. [GOC:ai, GOC:mah] |
neuron cellular homeostasis | biological process | The cellular homeostatic process that preserves a neuron in a stable, differentiated functional and structural state. [GOC:BHF, GOC:mah] |
positive regulation of ERK1 and ERK2 cascade | biological process | Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade. [GOC:mah] |
response to interleukin-1 | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-1 stimulus. [GOC:BHF, GOC:mah] |
modulation of excitatory postsynaptic potential | biological process | Any process that modulates the frequency, rate or extent of excitatory postsynaptic potential (EPSP). EPSP is a process that leads to a temporary increase in postsynaptic potential due to the flow of positively charged ions into the postsynaptic cell. The flow of ions that causes an EPSP is an excitatory postsynaptic current (EPSC) and makes it easier for the neuron to fire an action potential. [GOC:dos] |
NMDA selective glutamate receptor signaling pathway | biological process | The series of molecular signals initiated by glutamate binding to an NMDA-selective glutamate receptor on the surface of the target cell, followed by the movement of ions through a channel in the receptor complex, and ending with the regulation of a downstream cellular process, e.g. transcription. [GOC:dos, ISBN:9780071120005] |
regulation of spontaneous synaptic transmission | biological process | Any process that modulates the frequency, rate or extent of spontaneous synaptic transmission. [GOC:aruk, GOC:bc, PMID:15457210] |
cytosolic mRNA polyadenylation | biological process | Any process by which dormant, translationally inactive mRNAs become activated, or mRNAs become stabilized, via the elongation of their poly(A) tails in the cytosol. [PMID:21536428] |
negative regulation of long-term synaptic potentiation | biological process | Any process that stops, prevents or reduces the frequency, rate or extent of long-term synaptic potentiation. [GOC:BHF, GOC:TermGenie] |
positive regulation of long-term synaptic potentiation | biological process | Any process that activates or increases the frequency, rate or extent of long-term synaptic potentiation. [GOC:BHF, GOC:TermGenie] |
positive regulation of non-canonical NF-kappaB signal transduction | biological process | Any process that activates or increases the frequency, rate or extent of the non-canonical NF-kappaB cascade. [GOC:TermGenie] |
cellular response to amyloid-beta | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a amyloid-beta stimulus. [GO_REF:0000071, GOC:TermGenie, PMID:23555824] |
regulation of presynapse assembly | biological process | Any process that modulates the frequency, rate or extent of presynapse assembly. [GO_REF:0000058, GOC:bc, GOC:PARL, GOC:TermGenie, PMID:25533483] |
positive regulation of amyloid fibril formation | biological process | Any process that activates or increases the frequency, rate or extent of amyloid fibril formation. [GO_REF:0000058, GOC:aruk, GOC:bc, GOC:TermGenie, PMID:23106396] |
amyloid fibril formation | biological process | The generation of amyloid fibrils, insoluble fibrous protein aggregates exhibiting beta sheet structure, from proteins. [GOC:cvs, GOC:jj, GOC:ppm, GOC:sj, PMID:21148556, PMID:22817896, PMID:28937655, PMID:29654159] |
neuron projection maintenance | biological process | The organization process that preserves a neuron projection in a stable functional or structural state. A neuron projection is a prolongation or process extending from a nerve cell, e.g. an axon or dendrite. [GOC:kmv, PMID:25359212] |
positive regulation of T cell migration | biological process | Any process that activates or increases the frequency, rate or extent of T cell migration. [GOC:mah] |
central nervous system development | biological process | The process whose specific outcome is the progression of the central nervous system over time, from its formation to the mature structure. The central nervous system is the core nervous system that serves an integrating and coordinating function. In vertebrates it consists of the brain and spinal cord. In those invertebrates with a central nervous system it typically consists of a brain, cerebral ganglia and a nerve cord. [GOC:bf, GOC:jid, ISBN:0582227089] |